You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

hormone receptor-positive metastatic breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • (no location specified)
Nov 8, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in Duarte

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Nov 1, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Metastatic Breast Cancer Trial in Seoul (Pembrolizumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • Seoul, Korea, Republic of
    Yonsei Cancer Center at Yonsei University Health System
Mar 14, 2022

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

QOL of HR-Positive Metastatic BC Treated in First-line Setting:

Enrolling by invitation
  • Quality of Life
  • Breast Neoplasm Female
  • Quality of Life
  • São Paulo, Brazil
    Hospital Pérola Byington
Mar 10, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

HR+ Metastatic Breast Cancer Patients Previously Treated With

Recruiting
  • Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Mar 3, 2022

HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal

Active, not recruiting
  • HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
  • +2 more
  • Ulm, Baden-Württemberg, Germany
    University Hospital Ulm -Department of Gynecology
Jul 27, 2022

Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer Trial in Germany (Abemaciclib +

Recruiting
  • Hormone Receptor-positive Metastatic Breast Cancer
  • HER2-negative Metastatic Breast Cancer
  • Abemaciclib + Aromatase Inhibitor
  • Abemaciclib + Fulvestrant
  • Amberg, Germany
  • +32 more
Jan 17, 2023

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

Recruiting
  • Breast Cancer
  • Saint Louis, Missouri
  • +2 more
Jan 12, 2023

Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

Not yet recruiting
  • Hormone Receptor-positive Breast Cancer
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Oct 5, 2022

Real-World Data on First-line Treatment of Hormone

Recruiting
  • Breast Cancer
    • Porto Alegre, Rio Grande Do Sul, Brazil
      CPO
    Aug 15, 2022

    Metastatic Breast Cancer, Hormone Receptor Positive Trial in United States (Palbociclib, Tamoxifen, Fulvestrant)

    Completed
    Has Results
    • Metastatic Breast Cancer
    • Hormone Receptor Positive
    • San Francisco, California
    • +8 more
    Feb 16, 2022

    Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Washington, Baltimore, Hackensack

    Active, not recruiting
    • Breast Cancer
    • +2 more
    • Washington, District of Columbia
    • +4 more
    Jan 31, 2023

    Advanced or Metastatic Breast Cancer Trial (PF-07220060, Fulvestrant, Everolimus)

    Not yet recruiting
    • Advanced or Metastatic Breast Cancer
    • (no location specified)
    Oct 24, 2023

    Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

    Active, not recruiting
    • Metastatic Breast Cancer
    • Hospitalet de Llobregat, Barcelona, Spain
    • +6 more
    Jan 23, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma Trial in

    Withdrawn
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +4 more
    • Bintrafusp Alfa
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 2, 2022